These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32618476)

  • 1. Biosimilars in oncology: key role of nurses in patient education.
    Waller CF; Friganović A
    Future Oncol; 2020 Sep; 16(25):1931-1939. PubMed ID: 32618476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nursing Roles: Clinical Implications Regarding Trends, Administration, and Education for Biosimilars in Oncology Practice.
    Zack E
    Clin J Oncol Nurs; 2018 Oct; 22(5):21-26. PubMed ID: 30239530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH; Jacobs IA
    Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars.
    Sugay J
    Clin J Oncol Nurs; 2018 Oct; 22(5):27-32. PubMed ID: 30239528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities and challenges in biosimilar uptake in oncology.
    Dolan C
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars in oncology: everybody agrees but nobody uses?
    Gyawali B
    Recenti Prog Med; 2017 Apr; 108(4):172-174. PubMed ID: 28492585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies.
    Armuzzi A; Avedano L; Greveson K; Kang T
    J Crohns Colitis; 2019 Feb; 13(2):259-266. PubMed ID: 30285235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: Exploring the History, Science, and Progress.
    Tariman JD
    Clin J Oncol Nurs; 2018 Oct; 22(5):5-12. PubMed ID: 30239529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approval Process: An Overview of Biosimilars in the Oncology Setting.
    Sowinski-Raff L
    Clin J Oncol Nurs; 2018 Oct; 22(5):13-18. PubMed ID: 30239527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Talking to patients about biosimilars.
    Janjigian YY; Bissig M; Curigliano G; Coppola J; Latymer M
    Future Oncol; 2018 Oct; 14(23):2403-2414. PubMed ID: 29856243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Education strategy for the implementation of oncology biosimilars essential for operational and patient safety in Alberta, Canada.
    Garg M; Chatterjee A; Chambers CR
    J Oncol Pharm Pract; 2021 Jul; 27(5):1189-1194. PubMed ID: 33896268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
    Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
    J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status of Biosimilars in Oncology.
    Camacho LH
    Drugs; 2017 Jun; 77(9):985-997. PubMed ID: 28477160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars: Considerations for Oncology Nurses
.
    Vizgirda V; Jacobs I
    Clin J Oncol Nurs; 2017 Apr; 21(2):E54-E60. PubMed ID: 28315542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding State Regulation of Biosimilars and Effect on Prescribers.
    Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
    J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinician's guide to biosimilars in oncology.
    Rugo HS; Linton KM; Cervi P; Rosenberg JA; Jacobs I
    Cancer Treat Rev; 2016 May; 46():73-9. PubMed ID: 27135548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The development of biosimilars in oncology].
    Jiang SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.